Drug Trial Radar · NCT05349214
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
506
Actual
Start
Aug 4, 2022
Primary completion
May 13, 2025
Study completion Apr 15, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)
Conditions
- Sjogren Syndrome
Interventions
VAY736Biological
ianalumab s.c.
PlaceboOther
placebo s.c.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plan A and B - Change from baseline in ESSDAI score at Week 48Time frame: 48 weeks
Locations
146 sites in 26 countries. Site status is shown where the registry gives one.
Providence Medical Foundation
Fullerton, California
Advanced Medical Research
La Palma, California
Bay Area Arthritis And Osteoporosis
Brandon, Florida
GNP Research
Cooper City, Florida
Sarasota Arthritis Res Ctr
Sarasota, Florida
Augusta University Georgia
Augusta, Georgia
North Georgia Rheumatology Group
Lawrenceville, Georgia
Clin Invest Specialists Inc
Orland Park, Illinois
Clinic of Robert Hozman
Skokie, Illinois
Clinical Investigation Specialists, Inc.
Wauconda, Illinois
University of Kansas Hospital
Kansas City, Kansas
Tufts School of Dental Medicine
Boston, Massachusetts
Arthritis Osteoporosis Assoc of NM
Las Cruces, New Mexico
St Lawrence Health System
Potsdam, New York
Arthritis and Osteoporosis
Charlotte, North Carolina
On Site Clinical Solutions Llc
Charlotte, North Carolina
RAO Research LLC
Oklahoma City, Oklahoma
West Tennessee Research Institute
Jackson, Tennessee
Ramesh C Gupta MD Memphis TN
Memphis, Tennessee
Prolato Clinical Research Center
Houston, Texas
First Outpatient Research Unit
San Antonio, Texas
Advanced Rheumatology of Houston
Spring, Texas
Arthritis Northwest PLLC
Spokane, Washington
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Quilmes, Buenos Aires, Argentina
Novartis Investigative Site
San Miguel Tucuman, Tucumán Province, Argentina
Novartis Investigative Site
Maroochydore, Queensland, Australia
Novartis Investigative Site
Woodville South, South Australia, Australia
Novartis Investigative Site
Hobart, Tasmania, Australia
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Novartis Investigative Site
Curitiba, Paraná, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Burgas, Bulgaria
Novartis Investigative Site
Plovdiv, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Sydney, Nova Scotia, Canada
Showing 40 of 146 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.